Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
TEKTURNA HCT 300/25 |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Direct renin inhibitor + thiazide. |
| Generic Name |
|
Aliskiren 300mg, hydrochlorothiazide 25mg; tabs. |
| Also |
• TEKTURNA HCT 150/12.5
• TEKTURNA HCT 150/25
• TEKTURNA HCT 300/12.5
|
| Indications |
|
Hypertension. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Not for initial therapy. May substitute for previously titrated components, or switch to Tekturna HCT if inadequate response to either therapy alone, or if hypokalemia occurs with HCTZ monotherapy, or if dose-limiting effects occur with either component as monotherapy. Take consistently with regard to meals (absorption reduced by high-fat meals). ≥18yrs: One tablet once daily. May titrate up if BP uncontrolled after 2–4 weeks; max dose aliskiren 300mg/HCTZ 25mg. |
| Contraindications |
|
Anuria. Sulfonamide allergy. |
| Precautions |
|
Severe renal impairment (CrCl<30mL/min): not recommended. Severe renal disease. Correct salt/volume depletion before starting, or monitor closely. Hepatic dysfunction. Asthma. SLE. Monitor electrolytes. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Lithium toxicity (avoid). Potentiates antihypertensives, possibly non-depolarizing muscle relaxants. Potentiated by ketoconazole, atorvastatin. Antagonized by irbesartan, NSAIDs. May antagonize furosemide. ACTH, corticosteroids increase hypokalemia risk. Adjust antidiabetic drugs. Orthostatic hypotension potentiated by alcohol, CNS depressants. |
| Adverse Reactions |
|
Dizziness, diarrhea, cough, asthenia, arthralgia, elevated BUN/creatinine, ALT, uric acid; rare: angioedema (discontinue if occurs). |
| How Supplied |
|
Tabs—30, 90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
